Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2002-09-30
2003-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Seasonal Affective Depression (SAD) Study
NCT00069459
Prevention of Seasonal Affective Disorder
NCT00046241
A Safety, Efficacy and Tolerability Study of SEP-225289
NCT00584974
Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder
NCT00105989
Safety and Pharmacology Study of BMS-866949
NCT01124344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Investigational Seasonal Affective Disorder (SAD) Drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patient has a history or current diagnosis of anorexia nervousa or bulimia.
* Patient has recurrent summer depression more frequently than winter depression.
* Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder (PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
* Patient has initiated psychotherapy within the last 3 months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Study Site
Homer, Alaska, United States
Study Site
New Haven, Connecticut, United States
Study Site
Newark, Delaware, United States
Study Site
Wilmington, Delaware, United States
Study Site
Washington D.C., District of Columbia, United States
Study Site
Washington D.C., District of Columbia, United States
Study Site
Boise, Idaho, United States
Study SIte
Chicago, Illinois, United States
Study Site
Chicago, Illinois, United States
Study Site
Hoffman Estates, Illinois, United States
Study Site
Libertyville, Illinois, United States
Study SIte
Northfield, Illinois, United States
Study Site
Schaumburg, Illinois, United States
Study SIte
Greenwood, Indiana, United States
Study Site
Indianapolis, Indiana, United States
Study Site
Florence, Kentucky, United States
Study Site
Wellesley Hills, Massachusetts, United States
Study Site
Okemos, Michigan, United States
Study Site
Royal Oak, Michigan, United States
Study Site
Minneapolis, Minnesota, United States
Study Site
Moorestown, New Jersey, United States
Study Site
Piscataway, New Jersey, United States
Study Site
Amityville, New York, United States
Study Site
Lawrence, New York, United States
Study Site
New York, New York, United States
Study Site
Olean, New York, United States
Study Site
Staten Island, New York, United States
Study Site
Williamsville, New York, United States
Study Site
Cincinnati, Ohio, United States
Study Site
Cleveland, Ohio, United States
Study Site
Cleveland, Ohio, United States
Study Site
Independence, Ohio, United States
Study Site
Lyndhurst, Ohio, United States
Study Site
Toledo, Ohio, United States
Study Site
Eugene, Oregon, United States
Study Site
Portland, Oregon, United States
Study Site
Portland, Oregon, United States
Study Site
Salem, Oregon, United States
Study Site
Allentown, Pennsylvania, United States
Study Site
Philadelphia, Pennsylvania, United States
Study Site
Philadelphia, Pennsylvania, United States
Study Site
Lincoln, Rhode Island, United States
Study Site
Seattle, Washington, United States
Study Site
Madison, Wisconsin, United States
Study Site
Middleton, Wisconsin, United States
Study Site
Milwaukee, Wisconsin, United States
Study Site
West Allis, Wisconsin, United States
Study Site
Edmonton, Alberta, Canada
Study Site
Vancouver, British Columbia, Canada
Study Site
Miramichi, New Brunswick, Canada
Study Site
Sydney, Nova Scotia, Canada
Study Site
Markham, Ontario, Canada
Study Site
Mississauga, Ontario, Canada
Study Site
Hull, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
398149
Identifier Type: -
Identifier Source: org_study_id
NCT00300144
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.